INTRODUCTION
============

Traumatic brain injury (TBI) increases the likelihood of developing dementia and Alzheimer disease (AD) later in life ( [@nlw049-B1] ). β-Amyloid (Aβ) plaques, one of the neuropathological hallmarks of AD, are detected in approximately 30% of cases following moderate-to-severe TBI ( [@nlw049-B2] ), suggesting that TBI can trigger processes associated with amyloid deposition. However, only a subset of TBI patients develops Aβ plaques, suggesting that other factors can influence Aβ accumulation in the brain after injury.

The *APOE* gene is known to impact Aβ accumulation; polymorphisms in *APOE* result in 3 common alleles ( *E2, E3, E4* ) with *APOE4* being the strongest known genetic risk factor for sporadic, late-onset AD ( [@nlw049-B6] ). *APOE4* is also associated with increased Aβ plaque burden in the brains of AD patients ( [@nlw049-B7] , [@nlw049-B8] ), in acute postmortem TBI patients ( [@nlw049-B9] ), and in patients with chronic traumatic encephalopathy with concurrent amyloid deposition ( [@nlw049-B10] ).

The *APOE* gene encodes the 34 kDa protein apolipoprotein E (apoE), which is produced primarily by astrocytes and serves as a major lipid transport molecule in the CNS ( [@nlw049-B11] ). ApoE is hypothesized to play a role in a number of postinjury processes. For example, *apoe* mouse knockouts have greater cell death, axonal pathology, and behavioral deficits after brain injury versus wild type mice ( [@nlw049-B12] , [@nlw049-B13] ), and intracerebroventricular infusion of apoE reduces neuronal cell death in an animal model of global ischemia ( [@nlw049-B14] ). ApoE is also involved in clearance of Aβ from the brain by impacting the efflux of soluble Aβ across the blood-brain barrier via low-density lipoprotein receptor-related protein 1 ( [@nlw049-B15] ), and by enhancing degradation of Aβ by enzymes such as neprilysin or insulin-degrading enzyme ( [@nlw049-B18] ). Bexarotene, a retinoic acid receptor (RXR) agonist, can be used to increase brain levels of murine apoE and apoE4 in mice ( [@nlw049-B19] , [@nlw049-B20] ).

We hypothesized that apoE mediates Aβ clearance after TBI, but that this function is impaired in *APOE4* carriers. To test this, we exposed C57Bl/6 and humanized *APOE* mice to a controlled cortical impact (CCI) model of TBI and examined apoE, amyloid precursor processing and Aβ ~40~ in the brain after injury. We report that there is an inverse relationship between soluble apoE and Aβ ~40~ after injury such that TBI-induced Aβ levels decrease as soluble apoE levels increase. This relationship is abolished in APOE4 mice, leading to prolonged accumulation of TBI-induced Aβ ~40~ after injury.

MATERIALS AND METHODS
=====================

Animals
-------

Male C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, ME) and were 3--6 months old at the time of injury. Male mice with genetic ablation of *Apoe* , *Apoe* tm1Unc/J homozygous ( *Apoe*^−/−^ ) mice, were purchased from Jackson Laboratories and were 3 months old at the time of injury. Colonies of human APOE targeted replacement mice are maintained at Georgetown University. These mice express human *APOE* alleles, in place of murine *Apoe* , under the control of the endogenous promoter ( [@nlw049-B21] ). Four- to 6-month-old male mice homozygous for human APOE3 or human APOE4 were used in this study. All procedures were carried out in accordance with protocols approved by Georgetown University Animal Care and Use Committee.

Controlled Cortical Impact
--------------------------

A moderate injury was induced using an electromagnetic Leica Impact One device (Leica Microsystems, Richmond, IL) with surgery, as previously described ( [@nlw049-B22] ). CCI occurred on the left parietal cortex at a speed of 5.25 m/s, a depth of 1.5 mm and duration of 0.1 second.

Drug Administration
-------------------

The RXR agonist bexarotene (Biotang, Inc., Lexington, MA) was suspended in 0.5% methylcellulose (Sigma-Aldrich, St. Louis, MO) with 2% Tween-20 (Sigma-Aldrich). For the pretreatment protocol in wild type and *ApoE*^−/−^ mice, the mice received 100 mg/kg of bexarotene ( [@nlw049-B23] ) or vehicle administered once daily for 5 days prior to injury or sham injury, and 1 additional dose 15 minutes after injury or sham injury by oral gavage at a final volume of 5 mL/kg. For the therapeutic protocol, APOE4 mice received 100 mg/kg of bexarotene ( [@nlw049-B23] ) or vehicle by oral gavage at a final volume of 5 mL/kg administered 15 minutes post-CCI or sham injury and then once daily for 6 days after injury for daily treatment over the 7 day survival period.

Sample Preparation and Biochemistry
-----------------------------------

Extractions, enzyme-linked immunosorbent assay (ELISA) and Western blotting were conducted as previously described ( [@nlw049-B22] ). Mice were perfused with ice-cold phosphate buffered saline (PBS); the brain was then extracted and a 5-mm-diameter sample of cortical tissue surrounding the lesion, or tissue corresponding to the area of lesion in sham mice, was excised by punch extraction and rapidly frozen on dry ice for storage at −80 °C until processing. Proteins were sequentially extracted first in sucrose buffer containing diethylamine (DEA) (Sigma-Aldrich) and then in radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich). The DEA-soluble fraction contains extracellular and cytosolic proteins whereas the RIPA fraction contains membrane-bound proteins. Endogenous murine Aβ ~40~ was quantified in the DEA-soluble fractions by ELISA (Wako Chemicals, Richmond, Virginia).

For Western blotting, proteins were separated by electrophoresis on SDS--PAGE gels. The primary antibodies used were full-length amyloid precursor protein (APP) and APP C-terminal fragment (C1/6.1, kind gift from Dr Paul Mathews, Nathan S. Kline Institute, Orangeburg, NY), BACE1 (ab5940, Millipore, Billerica, MA), murine apoE (ab20874, Abcam, Cambridge, MA), and human apoE (Abcam, ab7620).

Quantitative RT-PCR was conducted on the ipsilateral cortex of a separate cohort of C57Bl/6J mice or the ipsilateral hippocampus of APOE mice as described in Ref. [@nlw049-B24] . TaqMan probes against murine *Apoe* (Mm01307193_g1), human APOE (Hs00171168_m1) or GAPDH (4352339E) from Applied Biosystems (Foster City, CA) were used.

Statistical Analysis
--------------------

Data were analyzed using either 1-way ANOVA followed by Dunnett *posthoc* test comparing 1, 3, and 7 days to sham for time course experiments, 1-way ANOVA followed by Tukey *posthoc* test for bexarotene experiments, or a 2-way ANOVA followed by a Bonferroni posttest for genotype experiments. Tests, including correlations, were performed using GraphPad Prism (La Jolla, CA). Differences were considered significant when p \< 0.05.

RESULTS
=======

Biphasic Response of Soluble apoE After TBI in C57Bl/6 Mice
-----------------------------------------------------------

Soluble apoE levels were measured in the DEA extract from the ipsilateral cortex of C57BL/6J mice by Western blot. Soluble apoE protein was reduced by 39% at 1 day postinjury (p \< 0.05, [Fig. 1A](#nlw049-F1){ref-type="fig"} ). However, levels of soluble apoE recovered by 3 days postinjury, and were significantly elevated by 52% above sham levels at 7 days postinjury (p \< 0.001, [Fig. 1A](#nlw049-F1){ref-type="fig"} ).

![Experimental traumatic brain injury (TBI) causes a biphasic response in apolipoprotein E (apoE) protein levels. **(A)** Soluble apoE protein levels from the ipsilateral cortex of sham and TBI-injured C57BL/6 mice. Representative blots are shown. **(B)** Comparison of diethylamine-soluble apoE (DEA) and radioimmunoprecipitation assay-soluble apoE (RIPA) from ipsilateral cortex of C57BL/6 mice. **(C)***Apoe* mRNA quantified by RT-PCR from the ipsilateral cortex of a separate cohort of C57BL/6 mice. One-way ANOVA with Dunnett *post hoc* analysis comparing 1, 3, and 7 days to sham for all panels, except 1-way ANOVA with Tukey *post hoc* analysis for panel **B** ). \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.](nlw049f1p){#nlw049-F1}

Levels of apoE in the DEA and RIPA extracts were compared to determine whether a reduction in soluble apoE levels at 1 day post-TBI was due to a shift in solubility from the DEA to the RIPA fraction. Prior to injury, the DEA extract contains approximately twice the amount of apoE compared with the RIPA extract. However, at 1 day postinjury, levels of apoE in the DEA extract were decreased by 37% (p \< 0.05), whereas no change in levels of RIPA-soluble apoE was observed ( [Fig. 1B](#nlw049-F1){ref-type="fig"} ), indicating that the reduction of apoE protein is restricted to the soluble pool.

*Apoe* mRNA levels were measured by quantitative RT-PCR; a *poe* expression was increased by 4.3-fold at 7 days postinjury ( [Fig. 1C](#nlw049-F1){ref-type="fig"} ).

Levels of Soluble apoE and Aβ are Inversely Correlated in the Brain After TBI in C57Bl/6 Mice
---------------------------------------------------------------------------------------------

Aβ levels and APP processing in the injured cortex were assessed. TBI caused an increase in levels of endogenous murine Aβ ~40~ in the ipsilateral cortex of C57BL/6 mice. Aβ ~40~ levels peaked at 1 day postinjury with a 53% increase in the injured cortex compared with sham (p \< 0.001). Aβ ~40~ levels decreased slightly from this peak but remained significantly elevated at 3 days (29% increase vs sham; p \< 0.01), before returning to sham Aβ ~40~ levels at 7 days postinjury ( [Fig. 2A](#nlw049-F2){ref-type="fig"} ).

![Levels of DEA-soluble apoE and DEA-soluble Aβ are inversely correlated in the ipsilateral cortex after TBI. **(A)** Soluble Aβ ~40~ in the sham and injured cortex of C57BL/6 mice measured by ELISA. **(B)** Quantification of amyloid precursor protein (APP), β-site APP cleaving enzyme-1 (BACE1) and APP C-terminal fragments (APP-CTF) from RIPA-extracted ipsilateral cortex. Representative blots are shown. **(C)** Correlation curve of soluble apoE versus soluble Aβ ~40~ in the sham and injured C57BL/6 mouse brain up to 7 days postinjury. One-way ANOVA with Dunnett *post hoc* analysis comparing 1, 3, and 7 days, to sham. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001. ELISA, enzyme-linked immunosorbent assay.](nlw049f2p){#nlw049-F2}

To assess Aβ production, levels of APP, β-secretase cleaving enzyme-1 (BACE1), and the β-cleaved C-terminal fragment of APP (β-CTF) generated when APP is cleaved by BACE1 were measured by Western blot. Because cleavage of APP by BACE1 is the rate-limiting step in Aβ production, increased levels of β-CTF indicate increased processing of APP into Aβ. BACE1 levels were increased at 1 day (127% increase, p \< 0.05) and 3 days (205%, p \< 0.01) postinjury compared with sham ( [Fig. 2B](#nlw049-F2){ref-type="fig"} ). β-CTF levels were also increased at 1 day (70%, p \< 0.05) and 3 days (92%, p \< 0.01) postinjury, indicating increased cleavage of APP by BACE1 at 1 and 3 days ( [Fig. 2B](#nlw049-F2){ref-type="fig"} ).

Levels of soluble apoE and soluble Aβ ~40~ from the brains of individual mice showed a strong inverse correlation such that as the levels of soluble apoE increased, the levels of TBI-induced Aβ decreased (p \< 0.001, [Fig. 2C](#nlw049-F2){ref-type="fig"} ).

Pharmacologically Increasing apoE Levels Decreases Aβ Levels After TBI in C57Bl/6 Mice But Not in *Apoe*^−/−^ Mice
------------------------------------------------------------------------------------------------------------------

To test whether increasing soluble apoE levels in the brain could decrease the peak in Aβ ~40~ observed after injury, we used the RXR agonist bexarotene to increase levels of apoE in mice prior to injury. Similar to the previous experiment, TBI caused a 42% reduction in levels of soluble apoE in the injured cortex at 1 day post-TBI in vehicle-treated mice versus sham (p \< 0.001, [Fig. 3A](#nlw049-F3){ref-type="fig"} ). Bexarotene pretreatment partially reversed this TBI-induced reduction in soluble apoE levels at 1 day, that is soluble apoE levels in TBI mice receiving bexarotene were only reduced by 21% at 1 day postinjury compared with sham (p \< 0.05, [Fig. 3A](#nlw049-F3){ref-type="fig"} ). Compared with injured vehicle-treated mice, bexarotene-treated mice had 38% more soluble apoE in the injured cortex at 1 day post-TBI.

![Bexarotene (bex) attenuates apoE loss after TBI and reduces Aβ levels. **(A)** Soluble apoE protein from ipsilateral cortex of vehicle and bexarotene pretreated C57BL/6 mice at 1 day postinjury. **(B)** Soluble Aβ ~40~ from ipsilateral cortex of vehicle and bexarotene pretreated C57BL/6 mice, measured by ELISA. **(C)** Correlation between DEA-soluble apoE and DEA-soluble Aβ ~40~ from sham vehicle (white circles), TBI vehicle (black circles) and TBI bexarotene (grey circles) pretreated mice. **(D)** Soluble Aβ ~40~ from ipsilateral cortex of vehicle and bexarotene pretreated *Apoe*^−/−^ mice at 1 day postinjury, measured by ELISA. Representative blots shown. One-way ANOVA with Tukey *post hoc* analysis comparing all columns. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001. ELISA, enzyme-linked immunosorbent assay.](nlw049f3p){#nlw049-F3}

TBI increased levels of Aβ ~40~ in vehicle treated-mice at 1 day postinjury, with Aβ ~40~ levels increased by 120% in the injured cortex of vehicle-treated mice compared with sham (p \< 0.001, [Fig. 3B](#nlw049-F3){ref-type="fig"} ). Treatment with bexarotene attenuated this peak in trauma-induced Aβ ~40~ , with levels of Aβ ~40~ in the injured cortex only increasing by 78% (p \< 0.01 vs vehicle-treated TBI mice, [Fig. 3B](#nlw049-F3){ref-type="fig"} ). Similar to the previous experiment, there was a strong inverse correlation between levels of soluble apoE and Aβ ~40~ in the brain after injury, with bexarotene-treated mice having more soluble apoE and less Aβ ~40~ in the brain than vehicle-treated mice (r ^2 ^ = ^ ^ 0.5073, p = 0.0004, [Fig. 3C](#nlw049-F3){ref-type="fig"} ).

To test whether apoE is required for the reduction of Aβ ~40~ levels after TBI by bexarotene we repeated our experiment in mice with genetic ablation of the *Apoe* gene ( *Apoe*^−/−^ mice). TBI increased levels of Aβ ~40~ in *Apoe*^−/−^ mice by 98% at 1 day postinjury (p \< 0.01, vehicle-treated mice compared with sham, [Fig. 3D](#nlw049-F3){ref-type="fig"} ). However, bexarotene treatment had no effect on the trauma-induced peak in Aβ ~40~ levels in *Apoe*^−/−^ mice, with levels of Aβ ~40~ in the injured cortex increasing by 85% (p \< 0.01 compared with sham; n.s. between treatments, [Fig. 3D](#nlw049-F3){ref-type="fig"} ), indicating that apoE may play a role in the rapid reduction of Aβ after TBI.

APOE4 Mice Have Prolonged Accumulation of Aβ ~40~ After TBI
-----------------------------------------------------------

To investigate if the accumulation of TBI-induced Aβ ~40~ is influenced by polymorphisms in the human APOE gene, we compared soluble apoE and soluble Aβ ~40~ levels in humanized APOE3 or APOE4 mice after injury.

The response of soluble apoE protein in APOE3 mice was similar to that of C57Bl/6 mice, with a decrease at 1 day (25% decrease) followed by a 138% increase at 3 days and a 311% increase at 7 days. This response did not occur in APOE4 mice ( [Fig. 4A](#nlw049-F4){ref-type="fig"} ). As previously reported, basal levels of apoE4 were 26% lower than basal levels of apoE3 ( [@nlw049-B24] ). The differences in the apoE protein response between APOE3 and APOE4 mice after injury were not due to differences in *APOE* expression because analysis of *APOE* mRNA levels showed identical patterns between genotypes ( [Fig. 4B](#nlw049-F4){ref-type="fig"} ).

![APOE4 mice have an abnormal apoE response and impaired clearance of Aβ after TBI. **(A)** Soluble apoE from ipsilateral cortex of sham and TBI injured APOE3 and APOE4 mice. **(B)***APOE* mRNA from ipsilateral hippocampus of APOE3 and APOE4 mice quantified by RT-PCR. **(C)** DEA-soluble Aβ ~40~ levels from the ipsilateral cortex of sham and TBI-injured APOE3 and APOE4 mice, measured by ELISA. **(D, E)** Correlation curve of soluble apoE versus soluble Aβ ~40~ in sham and injured APOE3 and APOE4 mouse brain up to 7 days postinjury. Representative blots shown. Two-way ANOVA with Bonferroni posttest. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.](nlw049f4p){#nlw049-F4}

Prior to injury, sham levels of Aβ ~40~ in APOE mice were similar between genotypes. Following injury, analysis of Aβ ~40~ levels by 2-way ANOVA revealed a significant effect of genotype (F ~1,40 ~ = ~ ~ 15.89, p \< 0.001), of time after injury (F ~3,40 ~ = ~ ~ 11.92, p \< 0.0001), and an interaction between the 2 variables (F ~3,40 ~ = ~ ~ 3.265, p \< 0.05) ( [Fig. 4C](#nlw049-F4){ref-type="fig"} ). *Posthoc* analysis revealed TBI increased levels of Aβ ~40~ in both APOE3 (71% increase over sham, p \< 0.01) and APOE4 mice (101% increase over sham, p \< 0.001) at 1 day, with no significant difference between genotypes. However, while TBI-induced Aβ ~40~ was rapidly cleared in APOE3 mice, TBI-induced Aβ ~40~ levels remained elevated in APOE4 mice at both 3 days (64% increase over sham, p \< 0.05) and 7 days (48% increase over sham, p \< 0.05) postinjury. Levels of Aβ ~40~ in APOE4 mice were significantly higher than in APOE3 mice at both 3 days (p \< 0.01) and 7 days (p \< 0.05) postinjury ( [Fig. 4C](#nlw049-F4){ref-type="fig"} ). There was a significant inverse correlation between soluble apoE and soluble Aβ ~40~ in APOE3 mice (p \< 0.01) ( [Fig. 4D](#nlw049-F4){ref-type="fig"} ), but not in APOE4 mice ( [Fig. 4E](#nlw049-F4){ref-type="fig"} ).

To assess Aβ production, levels of APP, BACE1, and β-CTF were measured by Western blot. APP processing was increased in both genotypes after TBI, but profiles of increased BACE1 and CTF levels did not differ between genotypes with both peaking at 3 days post-TBI ( [Fig. 5](#nlw049-F5){ref-type="fig"} ).

![APP-processing after TBI is similar between APOE3 and APOE4 targeted replacement mice. **(A--C)** Representative Western blots **(A)** and quantification of amyloid precursor protein (APP), β-site APP cleaving enzyme-1 (BACE1) and APP C-terminal fragments (APP-CTF) from RIPA-extracted ipsilateral cortex of sham and TBI injured APOE3 and APOE4 mice **(B, C)** . One-way ANOVA with Tukey *post hoc* test. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001 versus sham.](nlw049f5p){#nlw049-F5}

Increasing apoE4 Protein With Bexarotene Does Not Impact TBI-Induced Aβ ~40~ Levels in APOE4 Mice
-------------------------------------------------------------------------------------------------

Basal apoE4 protein levels were lower than basal apoE3 protein levels, and apoE4 levels did not respond to TBI to the same extent as apoE3. To determine if stimulating apoE levels in APOE4 mice could enhance clearance of TBI-induced Aβ and prevent the abnormal accumulation of Aβ in these mice after injury, APOE4 mice were given either vehicle or bexarotene starting 15 minutes post-TBI and then daily for 6 days.

Similar to our earlier findings, we observed no increase in soluble apoE levels in vehicle-treated APOE4 mice at 7 days post-TBI ( [Fig. 6A](#nlw049-F6){ref-type="fig"} ). However, 7 days treatment with bexarotene caused a 81% increase in apoE in injured APOE4 mice compared with sham mice (p \< 0.05; [Fig. 6A](#nlw049-F6){ref-type="fig"} ).

![Bexarotene treatment increases apoE levels, but does not stimulate clearance of Aβ in APOE4 mice at 7 days postinjury. **(A)** Soluble apoE protein levels in the ipsilateral cortex of APOE4 mice at 7 days postinjury with or without bexarotene treatment. **(B)** Soluble Aβ levels in APOE4 mice at 7 days post-TBI with or without bexarotene treatment, compared with sham APOE4 mice treated with vehicle. One-way ANOVA with Tukey *post hoc* test. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001 versus sham APOE4.](nlw049f6p){#nlw049-F6}

Also similar to earlier results, TBI caused an increase in Aβ ~40~ levels in APOE4 TBI mice that remained elevated at 7 days postinjury (34%; p \< 0.05; [Fig. 6B](#nlw049-F6){ref-type="fig"} ). However, despite the increase in apoE4 levels, bexarotene treatment did not reduce Aβ ~40~ levels in APOE4 TBI mice (27% elevation compared with sham control; p \< 0.05; [Fig. 6B](#nlw049-F6){ref-type="fig"} ).

DISCUSSION
==========

In this study, we determined how TBI alters soluble apoE protein levels and apoe mRNA, studied the relationship between soluble apoE and Aβ ~40~ , and examined how APOE genotypes impact Aβ ~40~ accumulation after TBI. We found that TBI caused a biphasic response in soluble apoE levels, with an acute depletion of the soluble pool of apoE that rebounded as apoe mRNA expression increased in the subacute phase. We also found a strong inverse correlation between soluble apoE protein levels and soluble Aβ ~40~ levels in the 7-day period after TBI, with levels of TBI-induced Aβ ~40~ decreasing in the brain as soluble apoE levels recovered and increased. Further, we determined this was a causal relationship using pharmacological and genetic tools. Finally, we report that expression of the *APOE4* allele results in an aberrant apoE response to TBI, and a prolonged accumulation of Aβ ~40~ that is resistant to pharmacologic manipulation of apoE4 protein levels.

Studies in experimental TBI models have reported increased apoE protein in the brain after experimental TBI ( [@nlw049-B25] ), but here we found a biphasic response with an acute decrease in soluble apoE protein levels at 1 day, followed by an increase in apoE at 7 days. Our findings are consistent with studies of severe human TBI patients who show a 70% decrease in cerebrospinal fluid apoE acutely postinjury ( [@nlw049-B26] ). The major difference between our study and previous animal studies is that we selectively extracted soluble apoE, and not the total apoE pool, which explains why we see a different effect. We do not know what causes the decrease of soluble apoE after injury, but we have established that it is not explained by a shift from soluble to membrane-bound pools of apoE. Thus, we hypothesize that the initial decrease in apoE protein is reflective of degradation or efflux of apoE following injury. The degradation of apoE in the extracellular space can occur via secreted chymotrypsin-like serine protease ( [@nlw049-B27] ), and the activity of this protease is increased by over 50% in the ipsilateral cortex in the first 24 hours after experimental TBI ( [@nlw049-B28] ).

The later increase in apoE protein was primarily driven by increased *apoe* mRNA expression, which is regulated by the ligand-activated liver X receptor (LXR)/RXR transcription factor. LXR/RXR is activated by endogenous substrates including the cholesterol metabolite 24S-hydroxycholesterol. We have previously reported that TBI causes an increase in the cortical levels of the CYP46 enzyme responsible for production of 24S-hydroxycholesterol, beginning at 3 days postinjury ( [@nlw049-B29] ), potentially providing the endogenous signal for increased apoE production.

TBI is known to cause an increase in Aβ levels in both humans and animals. In humans, intra-axonal accumulation of Aβ occurs in almost all cases of fatal TBI ( [@nlw049-B30] , [@nlw049-B31] ); increased intracellular staining of Aβ occurs in 80% of severe TBI cases ( [@nlw049-B4] ); and acute amyloid plaques are found in 30% of acute moderate-to-severe postmortem TBI brains ( [@nlw049-B3] ). The published data suggest that Aβ production is a common event after TBI, but the events controlling aggregation and deposition can vary among TBI cases. Indeed, while multiple groups have reported increased levels of soluble Aβ in the brain after experimental TBI in animals ( [@nlw049-B32] ), the data on whether TBI increases amyloid deposition in animals remain controversial. In the present study, we again confirmed that TBI causes an acute increase in Aβ ~40~ production; however we also observed that Aβ ~40~ levels return rapidly to baseline, even while BACE1 and β-CTF levels remain elevated. It should be noted that the primary pathological species of Aβ in TBI is Aβ ~42~ ( [@nlw049-B4] , [@nlw049-B40] ), but in this study, we focused on the Aβ ~40~ species, primarily because of the low levels of Aβ ~42~ in C57Bl/6 mice. The prolonged increase in BACE1 and CTF, we observed in this study could contribute to the continued production of Aβ ~42~ after TBI. We do not believe this to be the case because we have previously shown that TBI-induced changes in Aβ ~42~ follow an identical time course to that of Aβ ~40~ in C57Bl/6 mice ( [@nlw049-B41] ) and APP transgenic mice ( [@nlw049-B39] ). On the other hand, others have reported a prolonged increase in Aβ ~42~ in humanized APP mice following cortical impact injury ( [@nlw049-B33] ).

One factor that can influence Aβ clearance is the apoE protein ( [@nlw049-B17] , [@nlw049-B18] ), and the clearance of Aβ by apoE can be modified by *APOE* genotype ( [@nlw049-B42] ). This relationship is also found in TBI patient brains, in which only 10% of non-APOE4 carriers have amyloid plaques after TBI, whereas 35% of APOE4 heterozygotes and 100% of APOE4 homozygotes have brain Aβ deposits following injury ( [@nlw049-B9] ). A strong relationship between *APOE4* and Aβ after TBI is also reported in surgically resected cortical tissue from TBI patients ( [@nlw049-B43] ), where 50% of the Aβ plaque-forming TBI patients have *APOE4* genes.

The Aβ ~40~ peptide is associated with cerebral amyloid angiopathy (CAA), and previous studies on human postmortem tissue report CAA in acute TBI postmortem brains, with an 8.4-fold preference for *APOE4* carriers compared with non-APOE4 carriers ( [@nlw049-B44] ).

In animal studies, human APP/APOE4 mice have increased intracellular Aβ staining after TBI 1--12 weeks postinjury compared with APP/APOE3 mice ( [@nlw049-B37] ), and a separate study demonstrated that TBI resulted in increased fibrillar plaque deposition in APP/APOE4 mice at 3 months post-TBI versus APP/APOE3 mice ( [@nlw049-B45] ). In our study, we find that APOE3 and APOE4 mice have similar rates of APP processing, and Aβ ~40~ accumulation peaks at 1 day post-TBI with no difference between genotypes at this time point, as has been reported by other groups using CCI in APOE mice at this time point ( [@nlw049-B46] ). However, as we extended our observations past 1 day, we found that APOE4 mice had aberrant accumulation of Aβ ~40~ in the TBI brain compared with APOE3 mice up to 7 days postinjury. This prolonged accumulation does not appear to be due to increased production in the APOE4 mice because APP and APP-CTF levels are similar at all time points. Indeed, BACE1 protein levels in the APOE4 mice peak at less than 50% of BACE1 levels in APOE3 mice, again suggesting that the prolonged Aβ accumulation is not due to increased production. Given the known role of apoE in Aβ clearance, it appears that the apoE4 protein cannot mediate the rapid clearance of TBI-induced Aβ after injury.

APOE4 mice have lower basal levels of brain apoE compared with APOE3 ( [@nlw049-B47] ), and we also found lower levels of soluble apoE4 protein in our studies. In addition, APOE4 mice have an abnormal response to TBI with respect to soluble apoE levels. Our mRNA data show that *APOE* mRNA is expressed at similar levels in APOE3 and APOE4 mice after TBI, which is expected as both are driven by the endogenous mouse *Apoe* promoter. We did find that apoE protein is being produced in the APOE4 mice after injury, with large increases in RIPA-soluble apoE in both APOE3 (761% above APOE3 sham) and APOE4 mice (956% above APOE4 sham) at 7 days postinjury (not shown). However, APOE4 mice are unable to significantly increase soluble apoE protein levels in the subacute phase post-trauma. Because our data in C57Bl/6 mice suggest that increased levels of soluble apoE are important for the rapid return of Aβ ~40~ to baseline levels after TBI, we tested if increasing apoE4 protein levels could prevent the prolonged accumulation of Aβ ~40~ after TBI in APOE4 mice using bexarotene, which increases apoE protein levels in mice carrying the murine *apoe* and human *APOE4* genes ( [@nlw049-B19] , [@nlw049-B20] ). We found that 6 days of peripheral bexarotene administration greatly increased levels of soluble apoE4 after TBI. Despite this increase, it did not mediate a reduction in TBI-induced Aβ, which remained significantly elevated at 7 days postinjury. The inability of APOE4 mice to resolve increased levels of Aβ ~40~ in the brain 7 days after injury even with pharmacological enhancement of apoE4 levels further supports the hypothesis that apoE4 protein is dysfunctional at mediating Aβ clearance.

In conclusion, we report that there is an inverse relationship between soluble apoE and Aβ ~40~ after injury such that TBI-induced Aβ ~40~ levels decrease as soluble apoE levels increase. This relationship is abolished in APOE4 mice, leading to a prolonged accumulation of TBI-induced Aβ ~40~ after injury in these animals. These data may help explain the deposition of Aβ in *APOE4* carriers after TBI ( [@nlw049-B3] ), and increased incidence of Aβ plaque in *APOE4* postmortem TBI brains ( [@nlw049-B9] ).
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